Denali Therapeutics Inc. DNLI Deferred research and development funding liability
Deferred research and development funding liability at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept dnli:IncreaseDecreaseInDeferredLiabilityCapitalizedResearchAndDevelopmentCosts.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s deferred research and development funding liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s deferred research and development funding liability?
- Denali Therapeutics Inc. (DNLI) reported deferred research and development funding liability of -$5.99M in Q1 2026.
- How has Denali Therapeutics Inc.'s deferred research and development funding liability changed year-over-year?
- Denali Therapeutics Inc.'s deferred research and development funding liability decreased by 130.0% year-over-year, from $19.94M to -$5.99M.
- What does deferred research and development funding liability mean?
- This represents changes in liabilities specifically related to deferred funding for research and development activities, often originating from collaboration agreements or government grants. It tracks the timing difference between receiving cash for R&D and the actual recognition of those funds as revenue or expense offsets. This is a critical indicator of the company's ability to sustain its R&D pipeline through external funding sources.